About Us
Our Mission & Values
Leadership Team
Board of Directors
Partners
Corporate Giving
Responsibility
Press Releases
Medicines
Science
Pipeline
Clinical Trials
Publications
Treatment Access
Patients & Caregivers
Our Commitment to Patients
Patient Voices
CKD with Hyperphosphatemia
IBS-C
Chronic Idiopathic Constipation
Join Us
Working at Ardelyx
Benefits
Open Positions
Medical Professionals
Investors & Media
About Us
Our Mission & Values
Leadership Team
Board of Directors
Partners
Corporate Giving
Responsibility
Press Releases
Medicines
Science
Pipeline
Clinical Trials
Publications
Treatment Access
Patients & Caregivers
Our Commitment to Patients
Patient Voices
CKD with Hyperphosphatemia
IBS-C
Chronic Idiopathic Constipation
Join Us
Working at Ardelyx
Benefits
Open Positions
Medical Professionals
Investors & Media
Publications
Disease Area
Hyperphosphatemia
IBS-C
Year
All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Filter
Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na+/H+ Exchanger Isoform 3
ACS Medicinal Chemistry Letters
Efficacy of Tenapanor in Treating Patients with Irritable Bowel Syndrome with Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
The American Journal of Gastroenterology
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY)
Journal of the American Society of Nephrology
Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM)
Kidney360
Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality
Cardiorenal Medicine
Pages:
1
2
3
4
5
6
7
8
9
Load More
Sorry, nothing found in this query